The companies will collaborate on any commercial opportunities generated by the work together. Twist Biopharma, a division of Twist Bioscience, will then use its silicon-based DNA synthesis platform to generate a large number of precisely defined antibody sequences that can then be taken into proof-of-concept and preclinical development.
Specifically, Schrödinger will use its proprietary physics-based computational platform to model functional antibody segments that bind to a particular GPCR receptor. Under the terms of the agreement, each company will contribute their individual expertise in a highly collaborative manner to discover novel antibody therapeutics. 15, 2020– Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced today a collaboration with Schrödinger, Inc., a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ technology platforms together to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets. SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jan. Course: Introduction to Synthetic Biology.Biomanufacturing, chemicals & materials.
0 kommentar(er)
